Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0VA0I
|
||||
| Former ID |
DCL000225
|
||||
| Drug Name |
Vorapaxar
|
||||
| Synonyms |
Vorapaxar
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Schering-Plough
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C29H33FN2O4
|
||||
| InChI |
InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1
|
||||
| InChIKey |
ZBGXUVOIWDMMJE-QHNZEKIYSA-N
|
||||
| CAS Number |
CAS 618385-01-6
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Thrombin receptor | Target Info | Antagonist | [537151], [537189], [537571] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| PANTHER Pathway | Angiogenesis | ||||
| Blood coagulation | |||||
| Pathway Interaction Database | PAR1-mediated thrombin signaling events | ||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| IL1 and megakaryotyces in obesity | |||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Hematopoietic Stem Cell Differentiation | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Thrombin signalling through proteinase activated receptors (PARs) | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| Ref 533123 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | ||||
| Ref 540647 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4047). | ||||
| Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| Ref 537151 | Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009 Mar 14;373(9667):919-28. | ||||
| Ref 537189 | Novel antiplatelet strategies in acute coronary syndromes. Cleve Clin J Med. 2009 Apr;76 Suppl 1:S8-15. | ||||
| Ref 537571 | In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.